Wakelee, Heather

Institution/Organization
Stanford University and Stanford Cancer Institute

Primary Specialty
Medical Oncology

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
HW

Disclosure of Potential Conflicts
HW

COI Disclosure

Disclosures
AstraZeneca: Advisory board, Institutional, Personal
Janssen Advisory: board Personal
Daiichi Sankyo: Advisory board Personal
Blueprint: Advisory board Personal
Mirati: Advisory role Personal
Helsinn: Advisory role Personal
Fishawack: Facilitate LTD Ongoing series of lectures Personal
Medscape AND Research to Practice AND Curio Science: Multiple CME events Personal
MJH holdings (PER): Multiple CME events/conferences Personal
UpToDate: Royalty payments, Personal
Axis Medical Education and Nexus Oncology: CME events, Personal
ACEA Biosciences: Local PI on trial Institutional
Arrys Therapeutics: Local PI of trial Institutional
BMS (and former Celgene): Local PI of trial and coordinating PI of IIT for former Celgene Institutional
Clovis Oncology: Local PI of trial Institutional
Genentech/Roche: Local PI of trial and Steering Committee Member Institutional
Merck: Local PI of trial and Steering Committee Member Institutional
Novartis: Local PI Institutional
Xcovery: Local PI of trial and Steering Committee Member Institutional
Seagen: Local PI of trial Institutional

**COI Disclosure Certification**
HW

**Confidentiality Agreement**
HW

**Standards of Conduct Agreement**
HW

**IASLC’s Tax-Exempt Status**
HW

**COI Follow-Up**
Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?
Mitsudomi, Tetsuya

Institution/Organization
Kindai University Faculty of Medicine

Primary Specialty
Thoracic Surgery

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

Disclosure of Potential Conflicts

COI Disclosure

Disclosures
AstraZeneca: advisory role, speaker fee Institutional, Personal
MSD: advisor role, speaker fee Institutional, Personal
Novartis: advisor role, speaker fee Personal
MSD: advisor role, speaker fee Institutional, Personal
Bristol Myers Squibb: advisor role, speaker fee Personal
Ono: advisor role, speaker fee Personal
Pfizer: advisor role, speaker fee Personal
Boehringer Ingelheim: advisor role, speaker fee Institutional, Personal
Eli-Lilly: Speaker fee Personal
Chugai: advisor role, speaker fee, Institutional, Personal
Janssen: advisor Personal
Amgen: advisor role Personal
Daiichi-Sankyo: advisory role Personal
COI Disclosure Certification

Confidentiality Agreement

Standards of Conduct Agreement

IASLC's Tax-Exempt Status

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Amounts listed for institutions includes clinical trials and research grants.

Amounts listed for personal are mostly honoraria for the invited speeches, advisory role, and/or manuscript preparation.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Outside organizations:

- emeritus member, Japan Lung Cancer Society
- emeritus member, Japanese Association of Chest Surgery
- emeritus member, Japanese Society of Medical Oncology
- council member, Japan Surgical Society

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?
Van Schil, Paul

Institution/Organization
Antwerp University Hospital

Primary Specialty
Thoracic Surgery

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

**COI Policy Review and Compliance**
PVS

**Disclosure of Potential Conflicts**
PVS

**COI Disclosure**

**Disclosure List**

Disclosures
- AstraZeneca: External expert, Institutional
- MSD: External expert, Institutional
- National Cancer Institute (France): External expert, Institutional
- BACTS (Belgian Association for Cardio-Thoracic Surgery): Treasurer - board member, Institutional

**COI Disclosure Certification**
PVS

**Confidentiality Agreement**
PVS

**Standards of Conduct Agreement**
PVS

**IASLC's Tax-Exempt Status**
PVS

**COI Follow-Up**
Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?
Bezjak, Andrea

Institution/Organization
Princess Margaret Cancer Center

Primary Specialty
Radiation Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
AB

Disclosure of Potential Conflicts
AB

COI Disclosure

Disclosures
Princess Margaret Cancer Center: employment, Personal
University of Toronto: academic appointment, Personal
Astra Zeneca: Advisory Board, Personal

COI Disclosure Certification
AB

Confidentiality Agreement
AB

Standards of Conduct Agreement
AB

IASLC's Tax-Exempt Status
AB

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?
Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

I have no clinical trials with RT companies.
Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
yes, et

Disclosure of Potential Conflicts
et

COI Disclosure
I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification
et

Confidentiality Agreement
et

Standards of Conduct Agreement
difficult to read, et

IASLC’s Tax-Exempt Status
et

COI Follow-Up
Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.
Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?
Aerts, Joachim

Institution/Organization
Erasmus University Medical Center

Primary Specialty
Pulmonary Medicine

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
ja

Disclosure of Potential Conflicts
ja

COI Disclosure
Disclosures
MSD, BMS, Boehringer Ingelheim, Roche, Eli-Lilly: Consultancy and speaker
BIOCAD: speaker, consultant, DSMB member
Amphera: stock owner and scientific advisor

COI Disclosure Certification
ja

Confidentiality Agreement
ja

Standards of Conduct Agreement
ja

IASLC's Tax-Exempt Status
ja
Moreira Ferreira, Carlos Gil

Institution/Organization
Instituto Oncoclinicas

Primary Specialty
Medical Oncology

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
CGF

Disclosure of Potential Conflicts
CGF

COI Disclosure

Disclosures
I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification
CGF

Confidentiality Agreement
CGF

Standards of Conduct Agreement
CGF

IASLC's Tax-Exempt Status
CGF
Gray, Jhanelle

Institution/Organization
Moffitt Cancer Center

Primary Specialty
Medical Oncology

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
JG

Disclosure of Potential Conflicts
JG

COI Disclosure
Disclosures
Moffitt Cancer Center: Full Member, Department Chair and Program Leader
ASCO: Committee Member and Chair Elect; Grant Reviewer
IASLC: Committee Chair
EMD Serono: Consultant/Advisor; Research Support
Loxo: Research Support
AstraZeneca: Advisory/Consultant; Research Support
BluePrint Medicine: Advisor
BMS: Consultant/Advisor
BMS: Research Support
Novartis: Research Support
Eli Lilly: Consultant/Advisor
Ludwig Institute: Research Support
Genentech: Research Support
BI: Research Support
Merck: Consultant/Advisor
Merck: Research Support
Pfizer: Research Support
Novartis: Consultant/Advisor
Inivata: Consultant/Advisor
Sanofi: Advisor
SWOG: Lung Committee member; Lung Working Group member; LUNGMAP committee member; LUNGMAP study Chair
AACR: Abstract Panel Review Member

**COI Disclosure Certification**

JG

**Confidentiality Agreement**

JG

**Standards of Conduct Agreement**

JG

**IASLC's Tax-Exempt Status**

JG
Herbst, Roy

Institution/Organization
Yale Cancer Center

Primary Specialty
Medical Oncology

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
RSH

Disclosure of Potential Conflicts
RSH

COI Disclosure

Disclosures
AstraZeneca: Pharmaceuticals Consulting, Personal
EMD Serono Inc.: Consulting, Personal
Immunocore: Consulting, Personal
Johnson and Johnson: Consulting, Personal
Merck & Company, Inc: Consulting, Personal
Mirati Therapeutics: Consulting, Personal
Novartis Oncology: Consulting, Personal
STCube Pharmaceuticals, Inc: Consulting, Personal
Xencor, Inc: Consulting, Personal
AstraZeneca: Pharmaceuticals Research (Clinical Trials), Institutional
Genentech/Roche: Research (Clinical Trials), Institutional
Merck & Company, Inc: Research (Clinical Trials), Institutional
Immunocore Holdings Limited: Board Member (non-executive/independent), Personal
to include stock options in 2021
Junshi Biosciences Co., Ltd.: Board Member (non-executive/independent), Personal
Cybrexa Therapeutics: Consulting, Personal
eFFECTOR Therapeutics, Inc.: Consulting, Personal
Eli Lilly and Company: Consulting, Personal
I-Mab Biopharma: Consulting, Personal
Next Cure: Consulting, Personal
Bolt Biotherapeutics: Consultant, Personal, 2500 options (intrinsic value as of 4/21/2021: $0.00)

**COI Disclosure Certification**

RSH

**Confidentiality Agreement**

RSH

**Standards of Conduct Agreement**

RSH

**IASLC’s Tax-Exempt Status**

RSH

**COI Follow-Up**

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Those institutional amounts are the research study support.

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research.**

**Disclose any clinical trials you are conducting for institution fees.**

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

**Are you conducting any clinical trials where funds are paid to the institution?**

**Have you received any personal fees from outside CME companies?**

**Are you conducting clinical trials with any oncology equipment companies?**
Kim, Young Tae

Institution/Organization
Seoul National University

Primary Specialty
Thoracic Surgery

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
YTK

Disclosure of Potential Conflicts
YTK

COI Disclosure
Disclosures
Johnson and Johnson: Consult

COI Disclosure Certification
YTK

Confidentiality Agreement
YTK

Standards of Conduct Agreement
YTK

IASLC's Tax-Exempt Status
YTK
Quist, Morten

Institution/Organization
University hospital Copenhagen

Primary Specialty
Resp Therapy/Physiotherapy

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
MQ

Disclosure of Potential Conflicts
MQ

COI Disclosure

Disclosures
I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification
MQ

Confidentiality Agreement
MQ

Standards of Conduct Agreement
MQ

IASLC's Tax-Exempt Status
MQ
Sequist, Lecia

Institution/Organization
Massachusetts General Hospital

Primary Specialty
Medical Oncology

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
LS

Disclosure of Potential Conflicts
LS

COI Disclosure

Disclosures
AstraZeneca: Consulting
Janssen: Consulting
Genentech: consulting
Novartis: Clinical trial
AstraZeneca: Clinical Trial
Boehringer Ingelheim: Clinical trial
Genentech: clinical trial

COI Disclosure Certification
LS

Confidentiality Agreement
LS

Standards of Conduct Agreement
LS

IASLC's Tax-Exempt Status
LS
Tsao, Ming Sound

Institution/Organization
Princess Margaret Cancer Centre

Primary Specialty
Pathology

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
MST

Disclosure of Potential Conflicts
MST

COI Disclosure

Disclosures
University Health Network, Princess Margaret Cancer Centre: Senior Scientist and Consultant Pathologist
Merck: Medical Advisory Board meeting
Bayer: PI of a multi-institutional research grant to standardize IHC and NGS testing to detect NTRK fusions in cancer (2019-2021)
Bayer: Honoraria for Advisory Board consultancy meeting and meeting speaker
AstraZeneca: Advisory Board consultancy meeting
Bristol-Myers Squibb: Advisory Board consultancy meeting honorarium

COI Disclosure Certification
MST

Confidentiality Agreement
MST

Standards of Conduct Agreement
MST
IASLC's Tax-Exempt Status

MST
Ugalde, Paula

Institution/Organization
Institut Universitaire de Cardiologie et de Pneumologie de Québec - IUCPQ

Primary Specialty
Thoracic Surgery

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
PU

Disclosure of Potential Conflicts
PU

**COI Disclosure**
I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification
PU

Confidentiality Agreement
PU

Standards of Conduct Agreement
PU

IASLC's Tax-Exempt Status
PU
Zhou, Caicun

Institution/Organization
Tongji University Shanghai Pulmonary Hospital

Primary Specialty
Medical Oncology

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
ZCC

Disclosure of Potential Conflicts
ZCC

COI Disclosure
Disclosures
Lily China: honoraria as a speaker, Personal
Sanofi: honoraria as a speaker, Personal
BL: honoraria as a speaker, Personal
Roche China: honoraria as a speaker, Personal
MSD: honoraria as a speaker, Personal
Qilu: honoraria as a speaker, Personal
Hengrui: honoraria as a speaker and Advisor, Personal
Innovent Biologics: honoraria as a speaker and advisor, Personal
C-Stone: honoraria as a speaker, Personal
LUYE Pharma: honoraria as a speaker, Personal
TopAlliance Biosciences Inc: honoraria as a speaker and Advisor, Personal
Amoy Diagnostics: honoraria as a speaker, Personal

COI Disclosure Certification
ZCC
Confidentiality Agreement
ZCC

Standards of Conduct Agreement
ZCC

IASLC's Tax-Exempt Status
ZCC

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?